Previous business/academic article Next business/academic article
Business Articles Awards > General Antitrust

The importance of the new Competition innovation in life sciences

Ingrid Vandenborre, Competition Law Insight, 14 February 2017

See Ingrid Vandenborre's resume

Vote for this articleHelp

* Average
** Interesting
*** Good
**** Excellent
***** Must receive an Award!

Please note that the star(s) appearing on the article page before you have voted reflect the status of all votes registered to date.

Readers’ vote will close on February 9, 2018. Readers’ vote will allow you to nominate 1 article for each of the Awards, i.e., 10 Academic articles, 10 Business articles, and the best Soft Laws. The readers’ short-list of Academic and Business Articles will be communicated to the Board together with the 20 articles nominated by the Steering Committees. The Board will decide on the award-winning articles. Results will be announced at the Awards ceremony to take place in Washington DC on the eve of the ABA Antitrust Spring Meeting on April 10, 2018.

Click here to read the full article online

Increasingly, EU merger control enforcement seems to be focused on the impact a proposed transaction is likely to have on innovation. This is reflected both in the EU Commission’s substantive review of recent transactions, as well as its proposed legislative change to increase the EU Commission’s jurisdiction over proposed transactions involving highly valued target companies with limited sales revenues. Both are particularly relevant to the pharmaceutical sector.

Download our brochure